Hart Biologicals, the UK-based expert in cutting-edge in-vitro diagnostics, is expanding its product range in the global haemostasis market.   

The company will be promoting an extended range of platelet aggregation reagents and testing equipment directly to medical haemostasis laboratories around the world.

Paul Bates, Sales Manager at Hart Biologicals, said: “The new products give users the ability to diagnose beyond the established clinical platelet disorders such as von Willebrand Syndrome, Bernard Soulier Syndrome, Glanzmann Thrombasthenia, and Storage Pool Disease, by being able to directly assess the effectiveness of treatment with new anti-platelet agents such as clopidogrel, ticagrelor, prasugrel, ticlopidine and eptifibatide.

“Many of these new agents have been shown to exhibit dose-dependent responses so that so called drug-resistant effects have to be evaluated before patients can be stabilised on long term therapy. Similar to the well characterised phenomenon of aspirin-resistance.

“Customers will now get access to our expanded range of products which is more comprehensive than that of our competitors’; allowing more choice and greater scope for potential customers.

“The reliance of patients using antiplatelet therapy upon a new generation of drugs which act directly upon the receptor sites on the surface of the platelet means that laboratory evaluation of the likely effectiveness and suitability of a chosen agent has to be understood before a patient can enter long-term support using a drug.

“The main way of carrying out this assessment in the laboratory is using platelet aggregation studies, of which two methods are available; light transmittance aggregometry (LTA) and electrical impedance aggregometry (EIA)

“Hart Biologicals can supply a complete LTA package including instrumentation and reagents which uses plasma as the test matrix and by making available a custom-made adapter for use with a widely used EIA platelet aggregometry testing system which employs multiple electrode aggregometry (MEA) to test platelet function in whole blood.

“Hart Biologicals’ platelet aggregation reagents can be used with either testing approach.

“The plastic adapters have been designed especially to hold the Hart Biologicals’ reagent vials and tubes and to fit on all MEA platelet aggregometers installed in clinics around the world.”

Hart Biologicals offers ready-to-use reagents such as ADP, Collagen, Epinephrine, Ristocetin, Arachidonic Acid together with Prostaglandin E1, Trap 6, U46619 analogue and GPIIb/IIIa Antagonists.

Keighley Larkin, Regulatory Affairs Manager, said of the expansion: “We are specialists in our freeze-drying facilities and we are always focused on customers’ needs in order to make niche products specific to their requirements.

“By selling directly to the customer we can offer a complete customer service package. We can now add the customer care element directly to our customers and ensure that if anyone has any questions they can speak directly to us about it.”

For more information about the range of reagents Hart Biologicals develops click here.